Literature DB >> 15776286

Mechanistic insight into osteoclast differentiation in osteoimmunology.

Hiroshi Takayanagi1.   

Abstract

Recently a close relationship between the immune and skeletal systems or the interdisciplinary field called osteoimmunology has attracted much attention due to the observations that bone destruction is caused by an abnormal activation of the immune system in rheumatoid arthritis, and that mice lacking immunomodulatory molecules often exhibit an unexpected bone phenotype. Osteoclasts are cells of monocyte/macrophage origin that degrade the bone matrix. They are among the key players in the control of bone metabolism in health and disease. Receptor activator of NF-kappaB ligand (RANKL), a tumor necrosis factor (TNF) family cytokine, induces the differentiation of osteoclasts in the presence of macrophage-colony stimulating factor. RANKL activates TRAF6, c-Fos, and calcium signaling pathways, all of which are indispensable for the induction and activation of nuclear factor of activated T cells (NFAT) c1, the master transcription factor for osteoclastogenesis. The autoamplification of NFATc1 gene results in the efficient induction of osteoclast-specific genes. An AP-1 transcription factor complex containing c-Fos plays a crucial role in these processes, although results in conditional knockout mice show that Jun family members have a redundant role. The immunoreceptor tyrosine-based activation motif (ITAM) is an important signaling component for a number of receptors in the immune system including T-cell, B-cell, NK-cell, and Fc receptors, but its contribution to the skeletal system remains unclarified. In search for the calcium-mobilizing mechanism during osteoclastogenesis we determined that multiple immunoglobulinlike receptors associated with ITAM-harboring adaptors, Fc receptor common gamma chain (FcRgamma), and DNAX-activating protein (DAP) 12, are essential for osteoclastogenesis. In osteoclast precursor cells FcRgamma-associated receptors include osteoclast-associated receptor and paired immunoglobulinlike receptor A, while triggering receptor expressed in myeloid cells 2 and signal-regulatory protein beta1 preferentially associate with DAP12. In cooperation with RANKL these receptors activate phospholipase Cgamma and calcium signaling essential for the induction of NFATc1 through ITAM phosphorylation. Thus we have established the importance of the ITAM-mediated costimulatory signals in RANKL-induced osteoclast differentiation, which is analogous to the role of costimulatory signals in the immune system. Here we summarize recent advances in the study of signaling mechanism of osteoclast differentiation in the context of osteoimmunology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776286     DOI: 10.1007/s00109-004-0612-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  74 in total

1.  Bone versus immune system.

Authors:  J R Arron; Y Choi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 3.  Transcription factors of the NFAT family: regulation and function.

Authors:  A Rao; C Luo; P G Hogan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

5.  Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice.

Authors:  K N Weilbaecher; G Motyckova; W E Huber; C M Takemoto; T J Hemesath; Y Xu; C L Hershey; N R Dowland; A G Wells; D E Fisher
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

6.  Fra-1 replaces c-Fos-dependent functions in mice.

Authors:  A Fleischmann; F Hafezi; C Elliott; C E Remé; U Rüther; E F Wagner
Journal:  Genes Dev       Date:  2000-11-01       Impact factor: 11.361

7.  Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos.

Authors:  Koichi Matsuo; Deborah L Galson; Chen Zhao; Lan Peng; Catherine Laplace; Kent Z Q Wang; Marcus A Bachler; Hitoshi Amano; Hiroyuki Aburatani; Hiromichi Ishikawa; Erwin F Wagner
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

8.  The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.

Authors:  B R Wong; R Josien; S Y Lee; M Vologodskaia; R M Steinman; Y Choi
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

9.  Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1.

Authors:  K Muegge; T M Williams; J Kant; M Karin; R Chiu; A Schmidt; U Siebenlist; H A Young; S K Durum
Journal:  Science       Date:  1989-10-13       Impact factor: 47.728

10.  Impaired differentiation of osteoclasts in TREM-2-deficient individuals.

Authors:  Marina Cella; Cecilia Buonsanti; Carey Strader; Takayuki Kondo; Andrea Salmaggi; Marco Colonna
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  121 in total

1.  The hemoglobin receptor protein of porphyromonas gingivalis inhibits receptor activator NF-kappaB ligand-induced osteoclastogenesis from bone marrow macrophages.

Authors:  Yuji Fujimura; Hitoshi Hotokezaka; Naoya Ohara; Mariko Naito; Eiko Sakai; Mamiko Yoshimura; Yuka Narita; Hideki Kitaura; Noriaki Yoshida; Koji Nakayama
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Schmorl's nodes.

Authors:  Kwaku A Kyere; Khoi D Than; Anthony C Wang; Shayan U Rahman; Juan M Valdivia-Valdivia; Frank La Marca; Paul Park
Journal:  Eur Spine J       Date:  2012-04-28       Impact factor: 3.134

3.  IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).

Authors:  Zhihong Chen; Lingkai Su; Qingan Xu; Jenny Katz; Suzanne M Michalek; Mingwen Fan; Xu Feng; Ping Zhang
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

Review 4.  Nothing but skin and bone.

Authors:  F Patrick Ross; Angela M Christiano
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

5.  SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  J Orthop Res       Date:  2010-11       Impact factor: 3.494

Review 6.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

7.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Authors:  Kosuke Mizutani; Sudha Sud; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

8.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

9.  TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation.

Authors:  Betty Lamothe; William K Webster; Ambily Gopinathan; Arnaud Besse; Alejandro D Campos; Bryant G Darnay
Journal:  Biochem Biophys Res Commun       Date:  2007-06-11       Impact factor: 3.575

10.  Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.

Authors:  Yi-Kun Mou; Ping-Ping Zhang; Qiu-Xia Li; Zhi-Ming Lin; Ze-Tao Liao; Qiu-Jing Wei; Jie-Ruo Gu
Journal:  Clin Rheumatol       Date:  2015-04-26       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.